BIODESIX INC
No SEC Form 4 filings for $BDSX in the last 30 days.
BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bdsx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biodesix Announces Second Quarter 2026 Results and Highlights Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 milli
Biodesix (NASDAQ: BDSX) has filed an S-3 registration statement to allow Perceptive Credit Holdings IV, LP to resell up to 375,000 shares of common stock. These shares are issuable upon the exercise of warrants granted under multiple amendments to a credit agreement. Biodesix will not receive proceeds from the resale of these shares, but would receive proceeds if the warrants are exercised for cash.
Biodesix, Inc. (NASDAQ:BDSX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $32.50. The company reported better-than-expected quarterly earnings and revenue, and its stock has seen a recent increase of 5.1%. Insider buying has also been noted, with more shares purchased than sold in the last 90 days.
Over the past 7 days, alphai's AI scored 1 news story mentioning BDSX (BIODESIX INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent BDSX coverage spans financial news and earnings.
The 8-K provides fresh quarterly operating metrics and reaffirmed full-year guidance, which can drive near-term estimate revisions and sentiment.
The filing indicates potential increase in share availability due to resale, but no immediate cash inflow for Biodesix. The neutral sentiment suggests limited short-term price impact.
Biodesix, Inc. (NASDAQ:BDSX) has received a 'Moderate Buy' rating with an optimistic 12-month price target of $32.50. The company reported better-than-expected earnings and revenue, with a recent stock increase of 5.1%. Insider buying activity further supports a positive outlook.
Biodesix (BDSX) is currently rated as a 'Buy' by Wall Street analysts with a projected upside of approximately 86.45%. The stock's recent volatility is notable, but the consensus suggests strong future growth potential.
Biodesix, Inc. experienced a substantial reduction in institutional holdings but reported strong quarterly earnings, leading to a 10% stock price increase. The overall sentiment is moderately bullish, supported by positive earnings and institutional buying.
alphai scores every news story that mentions BDSX with an AI model for sentiment and relevance, and aggregates insider trades from BIODESIX INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bdsx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biodesix Announces Second Quarter 2026 Results and Highlights Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 milli
4 min readBiodesix (NASDAQ: BDSX) has filed an S-3 registration statement to allow Perceptive Credit Holdings IV, LP to resell up to 375,000 shares of common stock. These shares are issuable upon the exercise of warrants granted under multiple amendments to a credit agreement. Biodesix will not receive proceeds from the resale of these shares, but would receive proceeds if the warrants are exercised for cash.
2 min readBiodesix, Inc. (NASDAQ:BDSX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $32.50. The company reported better-than-expected quarterly earnings and revenue, and its stock has seen a recent increase of 5.1%. Insider buying has also been noted, with more shares purchased than sold in the last 90 days.
2 min readThis article analyzes Biodesix (BDSX) stock, highlighting a consensus "Buy" rating from Wall Street analysts and a significant projected upside of 86.45%. It discusses the average price target of $4.67 and outlines each analyst's specific rating and price target, providing context to the optimistic outlook despite recent stock volatility. The piece also includes key performance data and upcoming earnings information for investors to consider.
3 min readGSA Capital Partners LLP significantly reduced its stake in Biodesix, Inc. (BDSX) by selling 94.8% of its shares, retaining 48,342 shares valued at $365,000. Despite this, other institutional investors like XTX Topco Ltd increased their holdings, and institutional ownership remains at 20.96%. Biodesix also reported strong quarterly results, beating EPS and revenue estimates, which contributed to a 10% stock price increase, while analysts maintain a "Moderate Buy" rating with a consensus price target of $32.50.
3 min readBiodesix (NASDAQ:BDSX) CEO Scott Hutton recently sold 1,490 shares of the company's stock for approximately $19,042, reducing his ownership by 2.96%. This transaction follows previous insider sales in February and January. Analysts currently rate Biodesix as a "Moderate Buy" with a consensus price target of $32.50, while institutional ownership stands at around 21%.
2 min readRobin Harper Cowie, CFO of Biodesix (NASDAQ:BDSX), sold 535 shares of the company's common stock for approximately $6,834 on February 23, 2026. This transaction occurred after Cowie also exercised options to acquire 1,469 shares via restricted stock units on February 20, 2026. The sale comes as Biodesix shares have seen an 87.79% year-to-date surge, despite the company remaining unprofitable in the last twelve months, though recent preliminary Q4 and full-year 2025 results show significant revenue growth and EBITDA profitability.
3 min readBiodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing ...
2 min readLOUISVILLE, Colo., Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Biodesix, Inc. ( NYSE:BDSX ) , a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in ...
3 min readLOUISVILLE, Colo., Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- Biodesix, Inc. ( NASDAQ:BDSX ) , a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2025 after the close of trading on Monday, November 3.
2 min read
